These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33496327)

  • 21. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes.
    Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA
    Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
    Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
    Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression profile and injury sites in mice treated with Shiga toxin 2 and lipopolysaccharide as a Shiga toxin-associated hemolytic uremic syndrome model.
    Kume Y; Go H; Maeda R; Suyama K; Mori T; Kawasaki Y; Hashimoto K; Hosoya M
    Physiol Genomics; 2022 May; 54(5):153-165. PubMed ID: 35384732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
    Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
    J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crosstalk between Human Microvascular Endothelial Cells and Tubular Epithelial Cells Modulates Pro-Inflammatory Responses Induced by Shiga Toxin Type 2 and Subtilase Cytotoxin.
    Álvarez RS; Jancic C; Garimano N; Sacerdoti F; Paton AW; Paton JC; Ibarra C; Amaral MM
    Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31703347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome.
    Ray PE; Liu XH
    Pediatr Nephrol; 2001 Oct; 16(10):823-39. PubMed ID: 11605791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of the Nlrp3 Inflammasome Contributes to Shiga Toxin-Induced Hemolytic Uremic Syndrome in a Mouse Model.
    Song L; Xiao Y; Li X; Huang Y; Meng G; Ren Z
    Front Immunol; 2020; 11():619096. PubMed ID: 33552083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression of renal damage and tubular regeneration in pregnant and non-pregnant adult female rats inoculated with a sublethal dose of Shiga toxin 2.
    Fischer Sigel LK; Sánchez DS; Sacerdoti F; Zotta E; Silberstein C
    Microb Pathog; 2024 Jan; 186():106482. PubMed ID: 38086442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.
    Ozaki M; Kang Y; Tan YS; Pavlov VI; Liu B; Boyle DC; Kushak RI; Skjoedt MO; Grabowski EF; Taira Y; Stahl GL
    Kidney Int; 2016 Oct; 90(4):774-82. PubMed ID: 27378476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endogenous glucocorticoids modulate neutrophil function in a murine model of haemolytic uraemic syndrome.
    Gómez SA; Fernández GC; Camerano G; Dran G; Rosa FA; Barrionuevo P; Isturiz MA; Palermo MS
    Clin Exp Immunol; 2005 Jan; 139(1):65-73. PubMed ID: 15606615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice.
    Paixão-Cavalcante D; Botto M; Cook HT; Pickering MC
    Clin Exp Immunol; 2009 Feb; 155(2):339-47. PubMed ID: 19040606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined Action of Shiga Toxin Type 2 and Subtilase Cytotoxin in the Pathogenesis of Hemolytic Uremic Syndrome.
    Álvarez RS; Gómez FD; Zotta E; Paton AW; Paton JC; Ibarra C; Sacerdoti F; Amaral MM
    Toxins (Basel); 2021 Jul; 13(8):. PubMed ID: 34437406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effects of Shiga Toxin 1, 2 and Their Subunits on Cytokine and Chemokine Expression by Human Macrophage-Like THP-1 Cells.
    Brandelli JR; Griener TP; Laing A; Mulvey G; Armstrong GD
    Toxins (Basel); 2015 Oct; 7(10):4054-66. PubMed ID: 26473922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CCR2-dependent Gr1
    Pohl JM; Volke JK; Thiebes S; Brenzel A; Fuchs K; Beziere N; Ehrlichmann W; Pichler BJ; Squire A; Gueler F; Engel DR
    Eur J Immunol; 2018 Jun; 48(6):990-1000. PubMed ID: 29446073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model.
    Palermo MS; Alves Rosa MF; Van Rooijen N; Isturiz MA
    Clin Exp Immunol; 1999 Jun; 116(3):462-7. PubMed ID: 10361235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome.
    Siegler RL; Pysher TJ; Lou R; Tesh VL; Taylor FB
    Am J Nephrol; 2001; 21(5):420-5. PubMed ID: 11684808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of an experimental hemolytic uremic syndrome in rats.
    Zotta E; Lago N; Ochoa F; Repetto HA; Ibarra C
    Pediatr Nephrol; 2008 Apr; 23(4):559-67. PubMed ID: 18253762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls.
    Guirro M; Piazza RM; de Souza RL; Guth BE
    BMC Infect Dis; 2014 Jun; 14():320. PubMed ID: 24919599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality.
    Palermo M; Alves-Rosa F; Rubel C; Fernández GC; Fernández-Alonso G; Alberto F; Rivas M; Isturiz M
    Clin Exp Immunol; 2000 Jan; 119(1):77-83. PubMed ID: 10606967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.
    Locatelli M; Buelli S; Pezzotta A; Corna D; Perico L; Tomasoni S; Rottoli D; Rizzo P; Conti D; Thurman JM; Remuzzi G; Zoja C; Morigi M
    J Am Soc Nephrol; 2014 Aug; 25(8):1786-98. PubMed ID: 24578132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.